


# **VEGFR-3 SIGNATURE EXPRESSION BY HISTOLOGY TO CLASSIFY PATIENT POPULATION** FOR THE SELECTIVE VEGFR-3 INHIBITOR EVT801

For researchers:



Michael Paillasse<sup>1</sup>, Pierre-Benoit Ancey<sup>1</sup>, Gaelle Badet<sup>1</sup>, Anne Gomez-Brouchet<sup>2</sup>, Janik Selves<sup>2</sup>, Philippe Rochaix<sup>2</sup>, Maxime Battistella<sup>3</sup>, Céleste Lebbé<sup>4</sup>, Philippe Cassier<sup>5</sup>, Carlos Gomez Rocca<sup>4</sup>, Jean-Pierre Delord<sup>4</sup>, Francisco Cruzalegui<sup>1</sup>, Michael Esquerre<sup>1</sup>, Mark Whittaker<sup>6</sup> Lise Davenne<sup>1</sup>, John Friend<sup>7</sup>, Michael Fitzgerald<sup>7</sup>, James Garner<sup>7</sup> & Pierre Fons<sup>1</sup> <sup>1</sup>Evotec, Toulouse, France; <sup>2</sup>Institut Universitaire du Cancer Toulouse-Oncopole, France ; <sup>3</sup>Department of Pathology, AP-HP Hôpital Saint Louis, Paris, <sup>4</sup>Department of Dermatology, AP-HP Hôpital Saint Louis, Paris ; <sup>5</sup>Centre Léon Bérard, Lyon, France ; <sup>6</sup>Evotec, Abingdon, UK France ; <sup>7</sup>Kazia Therapeutics Ltd, Sydney, Australia; Toulouse France





EVT801 EVT	Cohort 2 T801 therapy Dose Cohor EVT801 monotherap	— — → EVT801
------------	---	--------------

- sarcomas. Combination with cancer immunotherapies would come next.